Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Matt Hancock

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved for emergency use by FDA as a booster

The authorisation is for those unable to receive an FDA-authorised mRNA bivalent booster

- PMLiVE

Moderna’s Omicron BA.1 booster shows superior antibody response over Spikevax

Data indicates that the superior response is sustained for at least three months

- PMLiVE

New study identifies gene associated with strong immune response to COVID-19 vaccines

Two out of every five people in the UK carry a version of an HLA gene called HLA-DQB1*06

- PMLiVE

Pfizer/BioNTech announce positive early data from trial of BA.4/BA.5 COVID-19 booster

A 30µg dose of the booster demonstrated a ‘substantial increase’ in antibody response

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster approved for emergency use by FDA in children five to 11 years

The doses will be shipped immediately, pending recommendation from the CDC

- PMLiVE

Shionogi signs licence agreement with MPP for COVID-19 oral antiviral treatment

The agreement aims to increase access to ensitrelvir in low- and middle-income countries

- PMLiVE

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

- PMLiVE

Shionogi’s antiviral COVID-19 treatment meets phase 3 primary endpoint

Ensitrelvir reduced the time taken to resolve five key symptoms

- PMLiVE

WHO reports warnings of ‘COVID-19 complacency’ from countries tracking global vaccine roll-out

Vaccination rates in low-income countries stand at 19% compared to almost 75% in high-income countries

- PMLiVE

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

- PMLiVE

COVID-19 linked to long-term neurologic disorders in new US study

Those infected with the virus had a 77% higher risk of developing memory problems versus control groups

- PMLiVE

Valneva actively discussing second-generation COVID-19 vaccine with prospective partner

The company also plans to send the remaining stocks of its current COVID-19 vaccine to international markets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links